奥贝胆酸与贝特类药物治疗原发性胆汁性胆管炎的多中心观察性研究比较
多中心观察性研究比较奥贝胆酸(OCA)与贝特类药物治疗对熊去氧胆酸应答不足的原发性胆汁性胆管炎患者的效果。不良事件报告率14.7%,以瘙痒为主(OCA组10.1%),非诺贝特停药更频繁。
要点
- OCA与贝特类均能改善UDCA应答不足PBC患者的生化指标和GLOBE评分。
- 贝特类降低ALP幅度更大,OCA降低ALT幅度更大。
- OCA联合贝特类可进一步改善ALP,但需注意瘙痒等不良事件。
核心结论
- OCA或贝特类二线治疗可改善UDCA应答欠佳PBC患者的肝脏生化指标和GLOBE评分。
- OCA与贝特类联合治疗同样可改善ALP。
研究设计与样本
- 多中心观察性研究,记录ColHai注册库中接受OCA、贝特类或两者联合治疗的患者为期一年的数据。
主要发现
- OCA组基线ALP显著高于贝特类组(P=0.01),血小板显著低于贝特类组(P=0.03)。
- 两种治疗均显著降低ALP、GGT和转氨酶并改善GLOBE评分;贝特类组白蛋白和IgM亦有改善。
- 贝特类降低ALP幅度更大,而OCA降低ALT幅度更大。
- OCA联合贝特类治疗期间ALP、GGT、ALT和GLOBE评分均显著改善。
- 不良事件报告率为14.7%(OCA组21.3%,非诺贝特组17.6%,苯扎贝特组10.7%),主要为瘙痒(OCA组10.1%);非诺贝特停药更频繁,主要因不耐受或不良事件。
临床怎么用
- 对UDCA应答不足的PBC患者,可考虑OCA或贝特类作为二线治疗以改善生化指标。
- 选择药物时需权衡疗效差异与不良反应,OCA治疗时注意瘙痒监测。
局限性
- 观察性研究设计,非随机对照,可能存在选择偏倚。
- 原文未报告样本量以外的统计效能或混杂因素控制细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness and adverse events of these treatments. METHODS: Data from patients included in the ColHai registry treated with OCA, fibrates, or both were recorded during a year, as well as adverse events and treatment discontinuation. RESULTS: Eighty-six patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. OCA group had baseline significantly higher alkaline phosphatase (ALP) (P = 0.01) and lower platelets (P = 0.03) than fibrates. Both treatments significantly decreased ALP, gamma-glutamyl transferase (GGT), and transaminases and improved Globe score. Albumin and immunoglobulin type M improved in the fibrates group. ALP decrease was higher under fibrates, whereas alanine aminotransferase decline was higher under OCA. Although baseline transaminases and GGT were higher in patients with OCA plus fibrates, significant ALP, GGT, alanine aminotransferase, and Globe score improvement were observed during triple therapy. Adverse events were reported in 14.7% of patients (21.3% OCA; 17.6% fenofibrate; 10.7% bezafibrate), mainly pruritus (10.1% with OCA). Discontinuation was more frequent in fenofibrate treatment mainly because of intolerance or adverse events. DISCUSSION: Second-line therapy with OCA or fibrates improves hepatic biochemistry and the GLOBE score in primary biliary cholangitis patients with suboptimal response to ursodeoxycholic acid. Simultaneous treatment with OCA and fibrates improved ALP as well.
引用
- Reig A, Álvarez-Navascués C, Vergara M, et al. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. Am J Gastroenterol. 2021. PMID: 34158466. doi:10.14309/ajg.0000000000001343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。